Fig. 5: Characterization of different plasma p-tau217 and tau-PETMTL groups in relevant trial measures. | Nature Aging

Fig. 5: Characterization of different plasma p-tau217 and tau-PETMTL groups in relevant trial measures.

From: Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

Fig. 5

This figure shows how different group compositions based on their baseline plasma p-tau217 and tau-PETMTL levels are related to various relevant trial metrics, including the annual mPACC5 slope (a, n = 1,376), the proportion of Aβ+ individuals (b, n = 1,473), the proportion of individuals from the entire population who would be included in a clinical trial based on the group definitions described on the x axis (c, all participants) and the proportion of ‘non-progressors’ on the mPACC5 (defined as slope > −0.016, see the Methods for details) (d, n = 1,376). Error bars in a represent the 95% CI. More efficient trials are expected with lower mPACC slopes and higher percentages of Aβ+ individuals and trial participants but lower percentages of non-progressors.

Back to article page